Use of MDM2 inhibitors for treatment of myelofibrosis

A technology of myelofibrosis and MDM2, applied in the field of drug combination for treating MF

Pending Publication Date: 2022-05-06
NOVARTIS AG
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although ruxolitinib has changed the treatment paradigm for patients with MF, there is no clear indication of a disease-modifying ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of MDM2 inhibitors for treatment of myelofibrosis
  • Use of MDM2 inhibitors for treatment of myelofibrosis
  • Use of MDM2 inhibitors for treatment of myelofibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] Certain terms used herein are described below. The compounds or biological agents of the invention are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0030] As used herein, the term "combination", "therapeutic combination" or "pharmaceutical combination" refers to a fixed combination in one dosage unit form, or a non-fixed combination, or a kit of parts for administration in combination , wherein two or more therapeutic agents may be administered independently at the same time or within time intervals, especially where these time intervals allow the combination partners to exhibit a cooperative (eg, synergistic) effect.

[0031] The term "combination therapy" refers to the administration of two or more therapeutic agents to treat the conditions or disorders being treated described in this di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of MDM2 inhibitors in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an MDM2 inhibitor, and b) at least one additional therapeutic agent, preferably rusotinib or a pharmaceutically acceptable salt thereof.

Description

[0001] The present invention relates to the use of MDM2 inhibitors and combinations thereof. technical field [0002] The present invention relates to the use of MDM2 inhibitors in the treatment of myelofibrosis (MF). The present invention also relates to a pharmaceutical combination comprising a) an MDM2 inhibitor and b) at least one additional therapeutic agent for the treatment of MF. Background technique [0003] Myeloproliferative neoplasms (MPNs) are a unique and heterogeneous group of hematologic disorders characterized by the proliferation and accumulation of mature myeloid cells, including myelofibrosis (MF), essential thrombocythemia (ET), and erythrocyte vera polycythemia (PV). Importantly, MF is the most severe form of Philadelphia chromosome-negative (ie, BCR-ABL1-negative) myeloproliferative neoplasms, with a prevalence estimated at 2.2 cases per 100,000 population. Myelofibrosis (MF) can present as a de novo disorder (PMF) or evolve from prior PV or ET (PPV-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/506A61K31/496A61P35/00
CPCA61K31/506A61K31/496A61P35/00A61K31/519A61K2300/00
Inventor A·埃利亚松N·格雷罗C·麦勒H·门森M·沃克罗夫斯卡K·G·J·瓦纳斯
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap